Table 1.
Demographics and clinical features of EGPA patients with COVID-19
| Literature cases (n = 2) | Our cases (n = 2) | Total (n = 4) |
|
|---|---|---|---|
| Age, median (min–max) | 42 (25–59) | 36.5 (33–40) | 36.50 (25–59) |
| Male, n (%) | 1 (50) | 0 | 1 (25) |
| Asthma, n (%) | 2 (100) | 2 (100) | 4 (100) |
| COVID-19 symptoms, n (%) | |||
| Fever | 1 (50) | 1 (50) | 2 (50) |
| Cough | 1 (50) | 1 (50) | 2 (50) |
| Malaise | 1 (50) | 1 (50) | 2 (50) |
| Myalgia | 1 (50) | 1 (50) | 2(50) |
| Dyspnea | 0 (0) | 1 (50) | 1 (25) |
| Headache | 1 (50) | 0 | 1 (25) |
| Nausea | 0 | 1 (50) | 1 (25) |
| Vomiting | 0 | 1 (50) | 1 (25) |
| Positive COVID-19 PCR test, n (%) | 2 (100) | 2 (100) | 4 (100) |
| Eosinophilia, n (%) | 1 (50) | 0 | 1 (25) |
| Lymphopenia, n (%)a | – | 2 (100) | 2 (50) |
| Ground-glass opacities in thorax CT, n (%) | 2(100) | 2 (100) | 4 (100) |
| Elevated CRP (> 5 mg/l), n (%) | 1(50) | 2 (100) | 3 (75) |
| EGPA treatment, n (%) | |||
| Low-dose glucocorticoidsb | 1 (50) | 1 (50) | 2 (50) |
| Rituximab | 1 (50) | 1 (50) | 2 (50) |
| Cyclophosphomide | 1 (50) | 0 | 1 (25) |
| Need for oxygen support, n (%) | 1 (50) | 1 (50) | 2 (50) |
| Mortality, n (%) | 0 | 0 | 0 |
EGPA eosinophilic granulomatosis with polyangitis, COVID-19 coronavirus disease 2019, n number, min minimum, max maximum, PCR polymerized chain reaction, CT computed tomography, CRP c-reactive protein
aliterature cases were missing lymphocyte count
bglucocorticoid dose < 10 mg prednisolone equivalent